A
Ansgar W. Lohse
Researcher at University of Hamburg
Publications - 541
Citations - 20339
Ansgar W. Lohse is an academic researcher from University of Hamburg. The author has contributed to research in topics: Autoimmune hepatitis & Medicine. The author has an hindex of 69, co-authored 470 publications receiving 16472 citations. Previous affiliations of Ansgar W. Lohse include University of Mainz.
Papers
More filters
Journal ArticleDOI
Overlap syndromes: The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue
Kirsten Muri Boberg,Roger W. Chapman,Gideon M. Hirschfield,Ansgar W. Lohse,Michael P. Manns,Erik Schrumpf +5 more
TL;DR: The IAIHG suggests that patients with autoimmune liver disease should be categorized according to the predominating feature(s) as AIH, PBC, and PSC/small duct PSC, respectively, and that those with overlapping features are not considered as being distinct diagnostic entities.
Journal ArticleDOI
Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma
Gerd Otto,Sascha Herber,Michael Heise,Ansgar W. Lohse,Christian Mönch,Fernando Bittinger,Maria Hoppe-Lotichius,Marcus Schuchmann,Anja Victor,Michael B. Pitton +9 more
TL;DR: Sustained response to TACE is a better selection criterion for LT than the initial assessment of tumor size or number, according to the multivariate analysis.
Journal ArticleDOI
Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe
Selidji T Agnandji,Angela Huttner,Madeleine E Zinser,Patricia Njuguna,Christine Dahlke,José Francisco Fernandes,Sabine Yerly,Julie-Anne Dayer,Verena Kraehling,Rahel Kasonta,A.A. Adegnika,Marcus Altfeld,Floriane Auderset,Emmanuel B. Bache,Nadine Biedenkopf,Saskia Borregaard,Jessica S Brosnahan,Rebekah Burrow,Christophe Combescure,Jules Alexandre Desmeules,Markus Eickmann,Sarah Katharina Fehling,Axel Finckh,Ana Rita Gonçalves,Martin P. Grobusch,Jay W. Hooper,Alen Jambrecina,Anita Lumeka Kabwende,Gürkan Kaya,Domtila Kimani,Bertrand Lell,Barbara Lemaître,Ansgar W. Lohse,Marguerite Massinga-Loembe,Alain Matthey,Benjamin Mordmüller,Anne Nolting,Caroline Ogwang,Michael Ramharter,Jonas Schmidt-Chanasit,Stefan Schmiedel,Peter Silvera,Felix R. Stahl,Henry M. Staines,Thomas Strecker,Hans Stubbe,Benjamin Tsofa,Sherif R. Zaki,Patricia E. Fast,Vasee S. Moorthy,Laurent Kaiser,Sanjeev Krishna,Stephan Becker,Marie-Paule Kieny,Philip Bejon,Peter G. Kremsner,Marylyn M. Addo,Claire-Anne Siegrist +57 more
TL;DR: RVSV-ZEBOV was reactogenic but immunogenic after a single dose and warrants further evaluation for safety and efficacy, and glycoprotein-binding antibody titers were sustained through 180 days in all participants.
Journal ArticleDOI
Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis
Michael P. Manns,Marek Woynarowski,Wolfgang Kreisel,Yoav Lurie,Christian Rust,Elimelech Zuckerman,Matthias J. Bahr,Rainer Günther,Rolf Hultcrantz,Ulrich Spengler,Ansgar W. Lohse,Ferenc Szalay,Martti Färkkilä,Markus Pröls,Christian P. Strassburg +14 more
TL;DR: Oral budesonide, in combination with azathioprine, induces and maintains remission in patients with noncirrhotic AIH, with a low rate of steroid-specific side effects.
Journal ArticleDOI
Immune tolerance: what is unique about the liver.
Gisa Tiegs,Ansgar W. Lohse +1 more
TL;DR: An interesting observation in this context is that knockout of IL-10 or PD-L1 (or the receptor PD-1) does not necessarily result in inflammatory liver damage whereas transgenic inhibition of TGFbeta signaling induces liver disease in mice resembling chronic cholangitis.